NEW YORK, Dec. 3, 2012 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:
Global Blood Banking And Blood Products Industry
http://www.reportlinker.com/p020749/Global-Blood-Banking-And-Blood-Products-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation
This report analyzes the worldwide markets for Blood Banking and
Blood Products in US$ Million by the following Product Segments:
Blood Components and Plasma Products (Whole Blood & Cellular
Components, & Plasma Fractions), and Equipment, Blood Tests and
Other Consumables (Includes blood screening and related QC
function, but excludes patient diagnosis). The report provides
separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World. Annual estimates and forecasts
are provided for the period 2010 through 2018. Also, a six-year
historic analysis is provided for these markets. The report
profiles 232 companies including leading blood banks such as AABB,
America's Blood Centers, American Red Cross, Canadian Blood
Services, Japan Red Cross, National Blood Foundation, and New York
Blood Center. Some of the leading players in Blood Bank Technology
& Supplies also discussed in this report include Beckman
Coulter Inc., Becton Dickinson and
Company, BioMerieux SA, CSL Behring LLC, Daxor Corporation, Fenwal
Inc., Gen-Probe, Inc., Haemonetics Corp, Hemagen Diagnostics Inc.,
Immucor Inc., Kawasumi Laboratories, Inc., Novartis Vaccines and
Diagnostics, Inc., Terumo Corporation, Terumo BCT Inc.,
ThermoGenesis Corp., and Velico Medical, Inc. Leading Players
discussed under the Plasma Fractionation segment include Baxter
International Inc., Beijing Tiantan Biological Products Co., Ltd.,
Bharat Serums, Bio Products Laboratory, Biotest AG, CSL Limited,
Grifols, S.A, Guizhou Taibang Biological Products Co., Ltd.,
Huanlan Biological Engineering Inc., Kedrion S.p.A., Laboratoire
Français du Fractionnement et des Biotechnologies, Octapharma AG,
OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co.,
Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Sanquin.
Market data and analytics are derived from primary and secondary
research. Company profiles are primarily based upon search engine
sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy
Reliability and Reporting Limitations I-1Disclaimers I-2Data
Interpretation & Reporting Level I-2Quantitative Techniques
& Analytics I-3Product Definitions and Scope of Study I-3Blood
Components and Plasma Products I-3Whole Blood & Cellular
Components I-4WBCs I-4RBCs I-4Platelets I-4Plasma Fractions
I-4Fresh Frozen Plasma I-4Albumin Fractions I-4Factor VIII
I-5Factor IX and Factor IX Complex I-5Fibrin/Thrombin I-5Equipment,
Blood Tests and Consumables I-5Automated Analyzers for Blood
Analysis I-5Blood Tests I-5Consumables I-6II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW II-1
Healthcare Scares Propel the Market II-1
Blood Transfusion Worldwide: A Kaleidoscope of Stark Contrasts
II-1
Worldwide Blood Banking and Blood Products Market at a
Glance
(All figures are 2012 estimates & CAGR is for the period
2010-2018) II-2
Current and Future Analysis II-2
Analysis by Geographic Region II-2
Analysis by Product Segment II-3
World Blood Components and Plasma Market Analysis in Units
II-3
Table 1: World Recent Past, Current & Future Analysis
for
Blood Components and Plasma by Region/Country - US, Europe,
Japan, and Rest of World
Markets Independently Analyzed with
Annual Consumption in Million Units for Years 2010 through
2018 (includes corresponding Graph/Chart) II-4
Table 2: World 9-Year Perspective for Blood Components andPlasma
by Region/Country - Percentage Breakdown of VolumeConsumption for
US, Europe, Japan, and Rest of World Marketsfor Years
2010, 2012 & 2018 (includes correspondingGraph/Chart) II-5Red
Blood Cells - A Key Blood Component and a Major Contributor
II-6Table 3: World Recent Past, Current & Future Analysis for
RedBlood Cells by Region/Country - US, Europe, Japan, and Restof World Markets Independently
Analyzed with AnnualConsumption in Million Units for Years 2010
through 2018(includes corresponding Graph/Chart) II-6
Table 4: World 9-Year Perspective for Red Blood Cells by
Region/Country - Percentage Breakdown of Volume Consumption
for US, Europe, Japan, and Rest of World Markets for Years
2010, 2012 & 2018 (includes corresponding Graph/Chart)
II-7
Blood Plasma Derivatives: An Overview II-7
Blood Plasma Sourcing II-7
Plasma Derived Products: Production II-8
IVIG II-8
Factor VIII II-8
Albumin II-8
Costs Associated with Plasma Derivatives Production II-8
Table 5: Global Plasma Derivatives Market: Percentage
Breakdown of Costs Associated with Production (includes
corresponding Graph/Chart) II-9
Player Scenario II-9
Table 6: Global Plasma Derived Products Market (2011):
Percentage Share Breakdown by Leading Players - Baxter, CSL,
Grifols (incl. Talecris), Octapharma, LFB, Biotest, Kedrion
and Others (includes corresponding Graph/Chart) II-9
Table 7: Global IVIg Market (2011): Percentage Breakdown
ofMarket Share for Leading Players (includes
correspondingGraph/Chart) II-10Indications Addressed by Major
Global IVIg Manufacturers II-10Table 8: Comparative Costs between
Plasma Protein Therapiesand Artificially Synthesized
Pharmaceuticals (includescorresponding Graph/Chart) II-10
Table 9: Global Plasma Market in the Recent Past (2008):
Market Shares of CSL Behring and Talecris in Select Plasma
Product Markets in terms of Revenues (includes corresponding
Graph/Chart) II-11
Competitive Landscape across Blood Banking, Blood Derived
Products and Plasma Production II-11
Table 10: Leading Players in the Global Blood Screening
Market (2011) (includes corresponding Graph/Chart) II-11
Table 11: Global Blood Derivatives Production (2011):Percentage
Share Breakdown of Leading Players - Baxter, CSL,Grifols (incl.
Talecris), Octapharma, Novo Nordisk, Bayer,Pfizer, Non-Profit
Organizations, and Others (includescorresponding Graph/Chart)
II-12
Table 12: Global Blood Plasma Manufacturing Market (2011):
Percentage Share Breakdown by Leading Players - Baxter, CSL,
Grifols (incl. Talecris), Pfizer, Novo Nordisk and Others
(includes corresponding Graph/Chart) II-12
Withdrawal of Octapharma's IVIG Proves Advantageous to
Competitors II-12
2. MARKET TRENDS & ISSUES II-14Key Trends in Blood
Banking/Pre-Transfusion Diagnostics II-14Demand Exceeds Supply:
Self-Sufficiency is the New Mantra II-14PrIME: An Innovative
High-Yield Process to Address Supply Dearth II-14Present State of
Plasma Fractionating Industry II-14Plasma Fractionation Industry
Concentrated in DevelopedCountries II-15PrIME Tackles the Issue of
Currently Unprocessable Plasma II-15New Infections - A Continuous
Threat II-15Safety and Availability: The Core Issues
II-16Decontamination: A Viable Process II-16New Processes for Safer
Blood Supply II-16Diagnostic Innovative Procedures Help Blood
Conservation II-17Autologous Transfusion Strapping up for High
Growth II-17Enzyme Converted Cells Set to Rule the Industry
II-17Blood Unavailability: Substitutes to the Rescue
II-17Transfusions: Hospitals Making Way for Others II-18Computer
Identification Helps Patients II-18SARS: A Case of Mistaken
Identity? II-18Pooling: Economical HIV Testing II-18Private Cord
Blood Banking: Flying High Despite Opposition II-19Automation of
Blood Banking - Nearing the Efficiency Frontier? II-19Automated
Instrumentation Taking the Front Seat II-19Table 13: World Market
for Blood Bank Technology (2011):Percentage Breakdown of Revenues
by Segment - Manual BloodBag Systems, Automated Systems, Component
Lab, CommercialPlasma, Blood Salvage, and Pathogen Inactivation
(includescorresponding Graph/Chart) II-20Plasma Market: Automation
Making Inroads II-20The RBC Market - Slow to Catch Up
II-20Automation of Testing - Yet to Mature II-20Automation to
Suffice Shortage Problems II-21How Near to the Efficiency Frontier?
II-21
3. PRODUCT OVERVIEW II-22
Blood Banking and Blood Products Industry II-22
Blood Components and Plasma Products II-22
Equipment, Blood Tests and Consumables II-22
Automated Analyzers for Blood Analysis II-22
Blood Tests II-22
Consumables II-23
Blood Collection Equipment II-23
Blood Collection Monitors II-23
Blood Donor Couches II-23
Blood Processing Equipment II-23
Blood Bank Centrifuges II-23
Plasma Thawing II-23
Blood Cell Separators II-24
Blood Storage Equipment II-24
Blood Bags II-24
Platelet Agitators II-24
Blood Bank Refrigerators II-24
Blood - A Primer II-24
Ionic Structure II-24
Blood Components and their Applications II-25
Blood Constituents II-26
Plasma II-26
Red Blood Cells (RBC) II-26
Blood Count II-27
Platelets II-27
White Blood Cells (WBC) II-27
Derivative Products of Blood or Plasma Fractions II-28
Plasma Protein and Fractionation II-28
Plasma Fractionation: Origins and Development II-28
Table 14: Plasma Fractionation Processes: Comparison of
Cohn IVIG and PrIME IVIG Based on Specific Characteristics
II-29
The Need II-29
Fresh Frozen Plasma II-29
Other Plasma Fractions II-29
Albumin Fractions II-30
Albumin Usage Rising in Profile, Wastage Worries Run Deep
II-30
Immunoglobulins II-30
Immunoglobulin Products Available in the Market (2012) II-30
Table 15: Leading Countries in IVIg Usage Rates in Grams per
1000 Population (includes corresponding Graph/Chart) II-31
Hyper-Immune Immunoglobulin II-31
Factor VIII II-31
Factor IX and Factor IX Complex II-31
Fibrin/Thrombin II-31
Consumption of Blood Based on Type of Surgery/Accident (In
Units) II-32
Table 16: World Market for Plasma Derivatives (2011):
Percentage Breakdown of Revenues by Product Type - IVIG,
Albumin, vWFactor & pdFVIII, Hyperimmunes, A1PI, Poly IG
and
Others (includes corresponding Graph/Chart) II-32
Recombinant Products II-32
Development Pipeline of Select rFVIII Products for
Hemophilia A Therapy: Breakdown by Product Name, Developing
Company, State of Development and Expected Market Launch
II-33
Table 17: Global Market for Recombinant Hemophilia Therapy
(2011): Percentage Share Breakdown for Leading Players
(includes corresponding Graph/Chart) II-33
Therapeutic Uses of Plasma Products II-33
Albumin Products II-33
Immunoglobulins II-34
Intravenous Immunoglobulin (IVIg) II-34
Normal Immunoglobulin (IMIg) II-34
CMV Immunoglobulin II-34
Hepatitis B Immunoglobulin II-34
Rh (D) Immunoglobulin II-34
Tetanus Immunoglobulin IM II-34
Zoster Immunoglobulin II-35
Table 18: Global Market for Immunoglobulins (IG) (2012):
Percentage Share Breakdown of Leading Products (includes
corresponding Graph/Chart) II-35
Plasma Derived Coagulant Products II-35
Biostate® II-35
Ceprotin® II-35
Factor VII Concentrate II-35
Factor XI Concentrates II-35
Feiba VH® Inhibitor Treatment II-36
Fibrogammin P® II-36
Monofix®-VF II-36
ProthrombinexTM-HT II-36
Thrombotrol®-VF II-36
4. BLOOD COLLECTION METHODS II-37Banking the Natural Blood
Resources II-37Blood Banks II-37Blood Banking II-37Blood
Transfusion II-37Role of Blood Banks II-37Blood Donor: The
Epicenter of the Process II-37Eligibility Criteria for the Donor
II-38The Basics of Blood Donation - Myths Exploded & Other
Facts II-38Table 19: Active Donors of Whole Blood and Apheresis
per1,000 of Population by Country/ Agency (includescorresponding
Graph/Chart) II-39
Table 20: Percentage Breakdown of Apheresis and Whole Blood
Donations by Country (includes corresponding Graph/Chart)
II-39
Collection Methods II-40
Blood Donation: The Process II-40
Types of Blood Donation II-40
Directed Blood Donations II-40
Autologous Blood Donation II-40
Alternative Usage of Patient's Own Blood II-40
General Blood Donation II-40
Hemodilution II-41
Wound Drainage II-41
Cell Saver II-41
The Method II-41
Blood Salvaging II-41
Blood Collection Centers II-41
Blood Collection Management System II-42
A Historical Retrospective II-42
Blood Collection Centers II-42
Types of Blood Collection Centers II-42
Cord Blood Banks II-42
Profit Collection Centers II-42
Military Blood Banks II-43
Hospital Blood Banks II-43
Community Blood Banks II-43
Non-Profit Collection Centers II-43
Blood Processing II-43
Blood Typing II-44
Rh Blood Group System II-44
ABO Blood Group System II-45
Blood Types and their Compatibility II-45
Table 21: Occurrence of Blood Groups Worldwide (In %)
(includes corresponding Graph/Chart) II-45
Blood Test II-46
Blood Culture II-46
The Costs II-46
History of Blood Banking II-46
5. THE CHANGING LANDSCAPE OF TRANSFUSION TECHNOLOGIES &
TESTS II-49Blood Transfusion: A Backdrop II-49Massive Transfusion
II-49Complications and Risks Due to Transfusion II-49Circulatory
Overload II-50Graft Versus Host Disease (GVHD) II-50Hemolytic
Transfusion Reactions II-50Iron Overload II-50Bacterial
Contamination II-50Thrombophlebitis II-50Allergic Reactions
II-50Air Embolism II-50Hyperkalaemia II-51Changing Role of Blood
Banking Technology II-51
6. BLOOD TRANSFUSION: THE PROCESS, TESTS/TECHNOLOGIES II-52
Cross Matching II-52
Blood Donor/Recipient Screening II-52
Blood Typing II-52
Leukoreduction II-52
Leukocyte Reduction Specification Standards/Filters II-53
Coombs Test II-53
7. ALTERNATIVES TO BLOOD TRANSFUSION: A REAL THREAT TO THE
INDUSTRY II-54Bloodless Surgery II-54Therapeutic Apheresis
II-54Plasmapheresis II-54Plateletpheresis II-54Leukapheresis
II-55Volume Expanders II-55Colloids II-55Albumin II-55Dextrans
II-55Hydroxyethyl Starch II-55Crystalloids II-55Blood Growth Factor
Therapies - Newer Alternatives to Transfusion II-56
8. BLOOD SUBSTITUTES II-57
Blood Substitutes Under Development by Manufacturers II-57
Synthetic Blood Manufacturers/Developers II-58
Alliance Pharmaceuticals Corp. (US) II-58
Biopure Corporation (US) II-58
Enzon Pharmaceuticals (US) II-59
Hemosol Inc. (Canada) II-59
Northfield Laboratories Inc. (US) II-59
Synthetic Blood International, Inc. (US) II-59
9. PRODUCT INNOVATIONS/LAUNCHES IN RECENT PAST - A
PERSPECTIVEBUILDER II-60America's Blood Centers Launches Management
System for BloodProducts II-60Biomatrica Introduces DNAstable®
Blood and DNAgard® Blood forWhole Blood Stabilization at Room
Temperature II-60Bio-Rad Launches Fully-Automated IH 1000 Blood
Screening System II-60Fenwal Receives US FDA Clearance for Fenwal
Amicus® SeparatorSystem II-61BD Unveils BD Microtainer® MAP
Microtube II-61Pall Releases Advanced Blood Filter II-62CaridianBCT
Rolls Out RBCX Protocol II-62ITL Launches TEGO™ Animal Blood
Collection Kit II-63Fenwal to Launch Modified ALYX Kit II-63QIAGEN
Launches New QIAsafe DNA Blood Products II-63Gambro Introduces New
Prismaflex eXeed™ System II-64AnaSpec Unveils 'SensoLyte® Rh110
Plasmin Activity Assay Kit II-64Typenex® Medical Rolls Out New
Barcode Blood Band II-65Olympus Introduces Hemoglobin A1c APT
Reagent for ChemistryAnalyzer System II-65BD Diagnostics Launches
BD BACTEC™ FX Blood Culture System II-65Beckman Coulter Launches
UniCel DxH 800 Coulter® CellularAnalysis System II-66
10. PRODUCT APPROVALS II-67
Quotient Receives FDA Approval for ALBAcyte Reagent RBC Products
II-67
EMIT Wins FDA Market Approval for Hypotherm X HX100 Device
II-67
MedPro Blood Collection Safety Products Obtain CE Mark II-67
Huaren Pharmaceutical GI and PD Solutions Obtain SFDA Approval
II-68
Cerus INTERCEPT Blood System Obtains Approval from Swissmedic
II-68
Abbott Obtains BLA Clearance from FDA for ABBOTT PRISM
Chagas
Test II-68
CaridianBCT Obtains FDA Approval for New 6.0 Trima Accel®
Automated Blood Collection System II-69
FDA Grants 510(K) Clearance for Expanded Use of Haemonetics
II-69
Fenwal Secures FDA Approval for New Platelet Additive Solution
II-69
BD Diagnostics Bags FDA Approval for BD Vacutainer® Rapid
Serum Tube II-70
Abbott Obtains FDA Approval for Abbott Prism HIV O Plus Test
II-70
11. PRODUCT APPROVALS IN THE RECENT PAST II-72Cerus Receives CE
Mark Approval for the INTERCEPT Blood Systemfor Platelets
II-72Haemonetics Wins FDA Approval for the ACP 215 System
II-72Biomerieux' Polycarbonate BacT/ALERT Receives US FDA Clearance
II-72Pall's eBDS Receives Green Signal from FDA II-73CardioPAT™
Surgical Blood Salvage System II-73PCS® 2 - Set to Enhance Plasma
Quality II-73Dade Behring's D-Dimer Assay Strapping up for Roll Out
II-73
12. RECENT INDUSTRY ACTIVITY II-74
Hologic to Take Over Gen-Probe II-74
ProMetic Obtains New Purchase under Octapharma Agreement
II-74
Grifols Takes Over Talecris II-74
IVD Acquisition Acquires Immucor II-75
Nordson Takes Over Value Plastics II-75
American Red Cross Takes Over RBC Collection Assets of HemaCare
II-75
Terumo Acquires CaridianBCT II-76
Bioniche to Take Over Plasvacc II-76
Logic Management Consulting to Take Over Guiyang Dalin
Biologic Technologies II-76
Humanwell Healthcare Acquires Further Stake in Zhongyuan
Ruide
Bio II-76
Red Cross and Mitsubishi Tanabe to Combine Plasma
Fractionation Business II-77
Fenwal Signs Definitive Agreement with Golden Meditech to
Set
Up JV II-77
Fenwal and Biolog-id Enter into Marketing Agreement II-77
GE Healthcare and Neste Jacobs
Enter into Partnership II-78
Cerus Enters into Supply Agreement with Etablissement
Francais
du Sang II-78
Transfusion Management Services and Vedant Enter into Partnership II-78
Global Healing Collaborates with Partners in Health II-79
ProMetic Expands Strategic Partnership with WIBP II-79
Amunix Partners with Biogen Idec II-80
Fenwal and GenesisBPS Ink Agreement for Blood-Specialty Products
II-80
Remi Enters into Collaboration
with Barkey for Indian Market II-80
Huaren Pharma to Set Up R&D Center for Blood Purification
II-80
China Biologic to Commence Commercial Collection of Plasma
at
Ninyang II-81
Grifols to Construct Plasma Fractionation Plant II-81
HLL Lifecare Inaugurates Second Blood Bag Plant in India II-81
13. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER
II-82Pall Inks Distribution Agreement with ASI II-82Cerus Inks Deal
with Swiss Red Cross for Deploying INTERCEPTBlood System II-82PT
Bio Farma to Construct New Albumin
Plant in Indonesia II-82NACO to
Establish Plasma Fractionation Facility in Chennai II-82Improve
Medical Instruments to Establish Subsidiary in Beijing II-83China
Biologic Products Obtains License for Plasma Collectionfrom
Shandong Province Health Department II-83Sorin Group Sells Two
Non-Core Product Lines to Cytomedix II-83Sigma to Lease QC Manager
Software to New Orleans based
BloodCenter II-83CaridianBCT's PRT System Chosen by Polish Health
Ministry II-84Micronics Obtains FDA Approval to Market ABORhCard
II-84HemaCare Signs Two New Blood Service Contracts
II-84Haemonetics Gains Rights to Alba's Full Line of Blood
TypingReagents II-85American Red Cross Inks 3-Year Deal with ITL
II-85Daxor's Idant Labs Bags Blood Banking Contract from RMSB&G
II-85Beckman Coulter Agrees to Distribute CellaVision
DigitalMorphology Products II-86Haemonetics Takes Over Global Med
II-86Therapure Biopharma Inks Long Term Pact with LFB
Biomedicaments II-86MRHC Obtains License for SafeTrace Tx Solution
of Global Med II-87Life Technologies to Acquire AcroMetrix
II-87Heska Enters into a Supply Agreement with Roche Diagnostics
II-87BLOOD Bank of Alaska Obtains License for Mediware's
LifeTrakTechnology II-88Europe and the US Expand Blood Banking
Agreement II-88Pfizer Acquires Wyeth II-89Baxter Inaugurates New
BLOOD Plasma Fractionation Facility inVienna II-89ProMetic Acquires
Majority Shareholding in PRDT II-89China Biologic to Collaborate
with IBT on Research & Development II-90Gen-Probe to Establish
Independent New Firm for IndustrialTesting II-90Haemonetics
Acquires SEBRA Blood Collection & Processing Unit II-91Beckman
Coulter Acquires Lab Based Diagnostics Business ofOlympus
II-92Golden Meditech and Fenwal to Establish a Blood
CollectionJoint Venture in China
II-92PRCS Inaugurates State-of-the-Art
Blood Bank II-92CSL and Talecris Terminate Merger Agreement
II-93Immucor Inks 5-Year Deal with Alverno II-93Gen-Probe Acquires
Tepnel and Renews Partnership with Novartis II-94Haemonetics Takes
Over Neoteric Technology II-94Haemonetics Acquires Altivation
Software II-95PacifiCord Sets Up Cord Blood Banking Facility in
Irvine II-95China Biologic Acquires 35% Stake in Xi`an Huitian
Blood Products II-95Octapharma Plans to Set Up Fractionation
Facility in Poland II-96Therapure
BioPharma Inks Development Services Deal with LFBBiotechnologies
II-96Biotest Acquires Blood Plasma Collection Center from Talecris
II-96Gen-Probe Expands and Extends Blood Screening Alliance
withNovartis II-96Celestial Biologicals Collaborates with GE
Healthcare forIndian Market II-97
14. FOCUS ON SELECT GLOBAL PLAYERS II-98
Leading Blood Banks II-98
AABB (US) II-98
America's Blood Centers (US) II-98
American Red Cross (US) II-98
Canadian Blood Services (Canada) II-99
Japan Red Cross Society (Japan)
II-99
National Blood Foundation (US) II-99
New York Blood Center (US) II-100
Leading Players in Blood Bank Technology and Supplies II-100
Beckman Coulter, Inc. (US)
II-100
Becton, Dickinson and Company (US) II-100
BioMerieux SA (France)
II-101
CSL Behring LLC (US) II-101
Daxor Corporation (US) II-101
Fenwal Inc. (US) II-102
Gen-Probe, Inc. (US) II-102
Haemonetics Corporation (US) II-102
Hemagen Diagnostics Inc. (US) II-103
Immucor Inc. (US) II-103
Kawasumi Laboratories, Inc. (Japan) II-104
Novartis Vaccines and Diagnostics, Inc (US) II-104
Terumo Corp. (Japan) II-105
Terumo BCT Inc (US) II-105
ThermoGenesis Corp. (US) II-105
Velico Medical, Inc. (US) II-106
Leading Players in Plasma Fractionation II-106
Baxter International Inc. (US) II-106
Beijing Tiantan Biological Products Co., Ltd (China) II-106
Bharat Serums and Vaccines Ltd (India) II-106
Bio Products Laboratory Ltd (UK) II-107
Biotest AG (Germany) II-107
CSL Limited (Australia)
II-107
Grifols, S.A (Spain) II-108
Guizhou Taibang Biological Products Co., Ltd (China) II-108
Huanlan Biological Engineering Inc. (China) II-109
Kedrion S.p.A. (Italy)
II-109
Laboratoire Français du Fractionnement et des
Biotechnologies
(France) II-109
Octapharma AG (Switzerland)
II-109
OMRIX Biopharmaceuticals Ltd (Israel) II-110
Shanghai RAAS Blood Products Co., Ltd. (China) II-110
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China) II-110
Sanquin (The Netherlands)
II-110
15. GLOBAL MARKET PERSPECTIVE II-111Table 22: World Recent Past,
Current & Future Analysis forBlood Banking and Blood Products
by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), LatinAmerica and Rest of World Markets
Independently Analyzed withAnnual Sales Figures in US$ Million for
Years 2010 through2018 (includes corresponding Graph/Chart)
II-111
Table 23: World Historic Review for Blood Banking and Blood
Products by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding
Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales
Figures
in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) II-112
Table 24: World 15-Year Perspective for Blood Banking andBlood
Products by Geographic Region - Percentage Breakdown ofValue Sales
for US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin
America and Rest of World Markets forYears 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-113Blood Banking and
Blood Products Market by Product Group/Segment II-114Table 25:
World Recent Past, Current & Future Analysis forBlood
Components and Plasma Products by Geographic Region -US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan),Latin
America and Rest of World Markets Independently Analyzedwith
Annual Sales Figures in US$ Million for Years 2010through 2018
(includes corresponding Graph/Chart) II-114
Table 26: World Historic Review for Blood Components and
Plasma Products by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin
America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) II-115
Table 27: World 15-Year Perspective for Blood Components
andPlasma Products by Geographic Region - Percentage Breakdown
ofValue Sales for US, Canada,
Japan, Europe, Asia-Pacific(excluding Japan), Latin
America and Rest of World Markets forYears 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-116
Table 28: World Recent Past, Current & Future Analysis
for
Blood Components and Plasma Products by Product Segment -
Whole Blood & Cellular Components, and Plasma Fractions
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-117
Table 29: World Historic Review for Blood Components andPlasma
Products by Product Segment - Whole Blood & CellularComponents,
and Plasma Fractions Markets IndependentlyAnalyzed with Annual
Sales Figures in US$ Million for Years2004 through 2009 (includes
corresponding Graph/Chart) II-118
Table 30: World 15-Year Perspective for Blood Components and
Plasma Products by Product Segment - Percentage Breakdown of
Value Sales for Whole Blood & Cellular Components, and
Plasma
Fractions Markets for Years 2004, 2011 & 2018 (includes
corresponding Graph/Chart) II-119
Table 31: World Recent Past, Current & Future Analysis
forWhole Blood & Cellular Components by Geographic Region -
US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), LatinAmerica and Rest of World Markets
Independently Analyzed withAnnual Sales Figures in US$ Million for
Years 2010 through2018 (includes corresponding Graph/Chart)
II-120
Table 32: World Historic Review for Whole Blood &
Cellular
Components by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding
Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales in
US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-121
Table 33: World 15-Year Perspective for Whole Blood &
CellularComponents by Geographic Region - Percentage Breakdown
ofValue Sales for US, Canada,
Japan, Europe, Asia-Pacific(excluding Japan), Latin
America and Rest of World Markets forYears 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-122
Table 34: World Recent Past, Current & Future Analysis
for
Plasma Fractions by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin
America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-123
Table 35: World Historic Review for Plasma Fractions
byGeographic Region - US, Canada,
Japan, Europe, Asia-Pacific(excluding Japan), Latin
America and Rest of World MarketsIndependently Analyzed with
Annual Sales Figures in US$Million for Years 2004 through 2009
(includes correspondingGraph/Chart) II-124
Table 36: World 15-Year Perspective for Plasma Fractions by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World
Markets for Years 2004, 2011 &
2018 (includes corresponding Graph/Chart) II-125
Table 37: World Recent Past, Current & Future Analysis
forEquipment, Blood Tests and Other Consumables by GeographicRegion
- US, Canada, Japan, Europe, Asia-Pacific (excludingJapan), Latin America and Rest of World Markets
IndependentlyAnalyzed with Annual Sales Figures in US$ Million for
Years2010 through 2018 (includes corresponding Graph/Chart)
II-126
Table 38: World Historic Review for Equipment, Blood Tests
and
Other Consumables by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin
America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) II-127
Table 39: World 15-Year Perspective for Equipment, Blood
Testsand Other Consumables by Geographic Region -
PercentageBreakdown of Value Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding
Japan), Latin America and Rest ofWorld Markets for
Years 2004, 2011 & 2018 (includescorresponding Graph/Chart)
(includes correspondingGraph/Chart) II-128III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Table 40: Blood and Organ Banks in the US (2011):
Percentage Share Breakdown of Revenues for Major Players -
American Red Cross, Musculoskeletal Transplant Foundation
Inc., Community Blood Center and Community Tissue Services
and CSL Ltd. (includes corresponding Graph/Chart) III-1
Table 41: US Blood Bank Industry (2011): Percentage
ShareBreakdown by Major Blood Suppliers (includes
correspondingGraph/Chart) III-2Market Trends III-2Recession Impacts
Blood Bank Reserves III-2US Blood Collection & Supply Profile
III-2Blood Group Distribution III-3Table 42: US Market for Blood
Banking and Blood Products:Percentage Break up of Blood Group by Rh
Factor (includescorresponding Graph/Chart) III-3
Table 43: Percentage Break up of Rh Blood Types in the US
by Racial Group (includes corresponding Graph/Chart) III-4
Blood Donated and Transfused Every Year III-4
Males Form the Major Chunk of Donors III-4
Cost of Blood III-4
SARS Scares: Blood Banks Feel the Heat III-4
Blood and Blood Preparations: A Review of Trade Statistics
III-5
Table 44: US Blood and Blood Preparations Market (2010 &
2011): Percentage Breakdown of Value Imports by Country of
Origin for Germany, UK,
Canada, Switzerland, Belgium and
Others (includes corresponding Graph/Chart) III-5
Table 45: US Blood and Blood Preparations Market (2010
&2011): Percentage Breakdown of Value Exports by Destinationfor
UK, Germany, Canada, Netherlands, Belgium and Others(includes corresponding
Graph/Chart) III-6
Table 46: US Market for Globulins (2011): Percentage
Breakdown by Leading Players for Baxter, Grifols (incl.
Talecris), CSL and Octapharma (includes corresponding
Graph/Chart) III-6
US Blood Components and Plasma Market Analysis in Units
III-7
Table 47: US Recent Past, Current & Future Analysis for
Blood Components and Plasma by Product Category - Red Blood
Cells (RBCs), Platelets, and Fresh Frozen Plasma Markets
Independently Analyzed with Annual Consumption in Million
Units for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-7
Table 48: US Historic Review for Blood Components andPlasma by
Product Category - Red Blood Cells (RBCs),Platelets, and Fresh
Frozen Plasma Markets IndependentlyAnalyzed with Annual Consumption
in Million Units for Years2004 through 2009 (includes corresponding
Graph/Chart) III-8
Table 49: US 15-Year Perspective for Blood Components and
Plasma by Product Category - Percentage Breakdown of Volume
Consumption for Red Blood Cells (RBCs), Platelets, and
Fresh Frozen Plasma for Years 2004, 2011 & 2018
(includes
corresponding Graph/Chart) III-8
Regulations Control Plasma Collection Industry III-9
Product launch III-9
Strategic Corporate Developments III-9
Key players III-13
B.Market Analytics III-21
Table 50: US Recent Past, Current & Future Analysis for
Blood Banking and Blood Products by Product Group/Segment -
Blood Components and Plasma Products (Whole Blood &
Cellular
Components, and Plasma Fractions); and Equipment, Blood
Tests and Other Consumables Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2010
through 2018 (includes corresponding Graph/Chart) III-21
Table 51: US Historic Review for Blood Banking and BloodProducts
by Product Group/ Segment - Blood Components andPlasma Products
(Whole Blood & Cellular Components, andPlasma Fractions); and
Equipment, Blood Tests and OtherConsumables Markets Independently
Analyzed with Annual SalesFigures in US$ Million for Years 2004
through 2009 (includescorresponding Graph/Chart) III-22
Table 52: US 15-Year Perspective for Blood Banking and Blood
Products by Product Group/ Segment - Percentage Breakdown of
Value Sales for Blood Components and Plasma Products (Whole
Blood & Cellular Components, and Plasma Fractions); and
Equipment, Blood Tests and Other Consumables Markets for
Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
III-23
2. CANADA III-24A.Market
Analysis III-24Current and Future Analysis III-24Blood Facts
III-24Bleeding Disorders - A Major Threat III-24'CSA-Z902-04' - A
Comprehensive Voluntary Blood Safety Standard III-24Blood and Blood
Preparations: Import & Export Scenario III-25Table 53: Canadian
Blood and Blood Preparations Market(2010 & 2011): Percentage
Breakdown of Value Imports byCountry of Origin for US, Switzerland, Germany,Netherlands, UK and Other
Countries (includes correspondingGraph/Chart) III-25
Table 54: Canadian Blood and Blood Preparations Market
(2010 & 2011): Percentage Breakdown of Value Exports by
Destination for US, France, UK,
Japan, Australia and Other
Countries (includes corresponding Graph/Chart) III-26
Strategic Corporate Development III-26
Canadian Blood Services - the Major Blood Bank III-27
B.Market Analytics III-28
Table 55: Canadian Recent Past, Current & Future
Analysis
for Blood Banking and Blood Products by Product
Group/Segment - Blood Components and Plasma Products (Whole
Blood & Cellular Components, and Plasma Fractions); and
Equipment, Blood Tests and Other Consumables Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-28
Table 56: Canadian Historic Review for Blood Banking andBlood
Products by Product Group/ Segment - Blood Componentsand Plasma
Products (Whole Blood & Cellular Components, andPlasma
Fractions); and Equipment, Blood Tests and OtherConsumables Markets
Independently Analyzed with Annual SalesFigures in US$ Million for
Years 2004 through 2009 (includescorresponding Graph/Chart)
III-29
Table 57: Canadian 15-Year Perspective for Blood Banking and
Blood Products by Product Group/Segment - Percentage
Breakdown of Value Sales for Blood Components and Plasma
Products (Whole Blood & Cellular Components, and Plasma
Fractions); and Equipment, Blood Tests and Other Consumables
Markets for Years 2004, 2011 & 2018 (includes
corresponding
Graph/Chart) III-30
3. JAPAN III-31A.Market
Analysis III-31Current and Future Analysis III-31Japan Witnesses
Surge in Imported Blood Products III-31Growing Market for Fresh
Frozen Plasma III-31Growing Use of Imported Albumin Based Blood
Products III-31The Goal of Self-Sufficiency III-32Strategic
Corporate Development III-33Key players III-33B.Market Analytics
III-35Table 58: Japanese Recent Past, Current & Future
Analysisfor Blood Banking and Blood Products by
ProductGroup/Segment - Blood Components and Plasma Products
(WholeBlood & Cellular Components, and Plasma Fractions);
andEquipment, Blood Tests and Other Consumables
MarketsIndependently Analyzed with Annual Sales Figures in
US$Million for Years 2010 through 2018 (includes
correspondingGraph/Chart) III-35
Table 59: Japanese Historic Review for Blood Banking and
Blood Products by Product Group/ Segment - Blood Components
and Plasma Products (Whole Blood & Cellular Components,
and
Plasma Fractions); and Equipment, Blood Tests and Other
Consumables Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-36
Table 60: Japanese 15-Year Perspective for Blood Banking
andBlood Products by Product Group/Segment - PercentageBreakdown of
Value Sales for Blood Components and PlasmaProducts (Whole Blood
& Cellular Components, and PlasmaFractions); and Equipment,
Blood Tests and Other ConsumablesMarkets for Years 2004, 2011 &
2018 (includes correspondingGraph/Chart) III-37
4. EUROPE III-38
A.Market Analysis III-38
Current and Future Analysis III-38
European Blood Banking and Blood Products Market at a
Glance (All figures are 2012 estimates & CAGR is for the
period 2010-2018) III-38
Market Trends and Issues III-39
Legislations on Payment for Donation Restrict Donors III-39
Government's Check on Healthcare Costs Pressurizes BCT
Manufacturers III-39
Purchasing System Witnesses Modifications III-39
EU Nations Marching Towards Self-Sufficiency in Blood and
Blood Products III-39
Blood Banking Devices Market III-39
Table 61: European Recent Past, Current & Future
Analysis
for Blood Banking Devices - Manual
Blood Collection,
Apheresis, and Autologous Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2010
through 2018 (includes corresponding Graph/Chart) III-40
Table 62: European Historic Review for Blood BankingDevices -
Manual Blood Collection, Apheresis,
andAutologous Markets Independently Analyzed with Annual
SalesFigures in US$ Million for Years 2004 through 2009(includes
corresponding Graph/Chart) III-41
Table 63: European 15-Year Perspective for Blood Banking
Devices - Percentage Breakdown of Value Sales for Manual
Blood Collection, Apheresis, and Autologous Markets for
Years 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-42
Table 64: European Blood Banking Devices Market
(2012):Percentage Breakdown of Value Sales by Geographic Regionfor
France, Germany, Italy, UK, Spain and Rest of Europe(includes corresponding Graph/Chart)
III-42A Snapshot of Health Care Systems Across Select EU Countries
III-43France III-43Germany III-43Italy III-43The UK III-43Spain
III-43B.Market Analytics III-44Table 65: European Recent Past,
Current & Future Analysisfor Blood Banking and Blood Products
by Geographic Region -France,
Germany, Italy, UK, Spain, Russia, and Rest ofEurope Markets
Independently Analyzed with Annual SalesFigures in US$ Million for
Years 2010 through 2018 (includescorresponding Graph/Chart)
III-44
Table 66: European Historic Review for Blood Banking and
Blood Products by Geographic Region - France, Germany,
Italy, UK, Spain, Russia, and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-45
Table 67: European 15-Year Perspective for Blood Banking
andBlood Products by Geographic Region - Percentage Breakdownof
Value Sales for France,
Germany, Italy, UK, Spain, Russiaand Rest of Europe Markets for
Years 2004, 2011 & 2018(includes corresponding Graph/Chart)
III-46
Table 68: European Recent Past, Current & Future
Analysis
for Blood Banking and Blood Products by Product
Group/Segment - Blood Components and Plasma Products (Whole
Blood & Cellular Components, and Plasma Fractions); and
Equipment, Blood Tests and Other Consumables Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-47
Table 69: European Historic Review for Blood Banking andBlood
Products by Product Group/Segment - Blood Componentsand Plasma
Products (Whole Blood & Cellular Components, andPlasma
Fractions); and Equipment, Blood Tests and OtherConsumables Markets
Independently Analyzed with Annual SalesFigures in US$ Million for
Years 2004 through 2009 (includescorresponding Graph/Chart)
III-48
Table 70: European 15-Year Perspective for Blood Banking and
Blood Products by Product Group/ Segment - Percentage
Breakdown of Value Sales for Blood Components and Plasma
Products (Whole Blood & Cellular Components, and Plasma
Fractions); and Equipment, Blood Tests and Other Consumables
Markets for Years 2004, 2011 & 2018 (includes
corresponding
Graph/Chart) III-49
4a. FRANCE III-50A.Market
Analysis III-50Current and Future Analysis III-50Strategic
Corporate Development III-50Key players III-50B.Market Analytics
III-52Table 71: French Recent Past, Current & Future Analysis
forBlood Banking and Blood Products by Product Group/Segment -Blood
Components and Plasma Products (Whole Blood &
CellularComponents, and Plasma Fractions); and Equipment,
BloodTests and Other Consumables Markets Independently Analyzedwith
Annual Sales Figures in US$ Million for Years 2010through 2018
(includes corresponding Graph/Chart) III-52
Table 72: French Historic Review for Blood Banking and Blood
Products by Product Group/Segment - Blood Components and
Plasma Products (Whole Blood & Cellular Components, and
Plasma Fractions); and Equipment, Blood Tests and Other
Consumables Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-53
Table 73: French 15-Year Perspective for Blood Banking andBlood
Products by Product Group/ Segment - PercentageBreakdown of Value
Sales for Blood Components and PlasmaProducts (Whole Blood &
Cellular Components, and PlasmaFractions); and Equipment, Blood
Tests and Other ConsumablesMarkets for Years 2004, 2011 & 2018
(includes correspondingGraph/Chart) III-54
4b. GERMANY III-55
A.Market Analysis III-55
Current and Future Analysis III-55
Biotest AG - A Key Player III-55
B.Market Analytics III-56
Table 74: German Recent Past, Current & Future Analysis
for
Blood Banking and Blood Products by Product Group/Segment -
Blood Components and Plasma Products (Whole Blood &
Cellular
Components, and Plasma Fractions); and Equipment, Blood
Tests and Other Consumables Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2010
through 2018 (includes corresponding Graph/Chart) III-56
Table 75: German Historic Review for Blood Banking and
BloodProducts by Product Group/ Segment - Blood Components
andPlasma Products (Whole Blood & Cellular Components,
andPlasma Fractions); and Equipment, Blood Tests and
OtherConsumables Markets Independently Analyzed with Annual
SalesFigures in US$ Million for Years 2004 through 2009 (includ
To order this
report:Blood_Supply,_Tissue_Banking_and_Transplantation
Industry: Global Blood Banking And Blood Products Industry
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker